MOPP (chemotherapy)
 | This article needs more reliable medical references for verification or relies too heavily on primary sources. (November 2021) |  |
MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen:
- Mustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD)
- Oncovin (also known as vincristine or VCR)
- Procarbazine
- Prednisone
Process
[edit]Mechlorethamine and vincristine are administered intravenously, while procarbazine and prednisone are pills taken orally.[medical citation needed] A newer Hodgkin lymphoma treatment is ABVD.[medical citation needed]
C-MOPP involves switching the nitrogen mustard from mechlorethamine to cyclophosphamide.[medical citation needed] C-MOPP is thus very similar to COPP, using the same four agents and differing at most in dosages and timing.[medical citation needed]
History
[edit]MOPP was the first combination chemotherapy that achieved a high success rate. It was developed at the National Cancer Institute.[citation needed]
Although no longer the most effective combination, MOPP is still used after relapse or where the patient has certain allergies or lung or heart problems which prevents the use of another regimen.[medical citation needed]
Side effects
[edit]There is 20% chance of developing a second cancer within 20 years of MOPP treatment. As a result, MOPP is rarely used for treatment for Hodgkin lymphoma.[1][unreliable medical source?] MOPP has been known to cause alopecia (hair loss) and skin sensitivity (especially to sunlight).[medical citation needed] Nausea, vomiting, and stomach ache are common, as are chills, constipation, and frequent urination.[medical citation needed] Permanent sterility is a frequent side effect.[medical citation needed]
See also
[edit]- ABVD – Chemotherapy regimen used to treat Hodgkin lymphoma
- BEACOPP
- CHOP – Treatment for non-Hodgkin lymphoma
- Stanford V